# Significance of Genetic Testing in Diagnosing Cholestatic Disease in Infants

**Authors:** Mahnoor Khan, Muhammad Umair Shehzad, Umaima M Khattak, Nida Zeeshan, Iqtadar Seerat

PMC · DOI: 10.7759/cureus.103031 · Cureus · 2026-02-05

## TL;DR

A rare genetic disorder causing cholestatic disease in infants is diagnosed through genetic testing and liver transplantation.

## Contribution

This case emphasizes the role of genetic testing in diagnosing low-GGT cholestasis in infants.

## Key findings

- Genetic testing confirmed a homozygous mutation in the HSD3B7 gene in a patient with cholestatic disease.
- Early biochemical evaluation and genetic testing are crucial for diagnosing rare bile acid synthesis defects.
- Liver transplantation was necessary due to progressive liver failure despite medical therapy.

## Abstract

Congenital bile acid synthesis defect type 1 (CBASD1) is an extremely rare autosomal recessive metabolic disorder caused by mutations in the HSD3B7 gene, resulting in defective bile acid synthesis and accumulation of hepatotoxic intermediates. We report a seven-month-old female infant born to consanguineous parents who presented with progressive jaundice since one month of age, severe pruritus, failure to thrive, and abdominal distension with hepatosplenomegaly. Biochemical evaluation revealed marked conjugated hyperbilirubinemia, elevated cholestatic enzymes, coagulopathy, and mild hypoalbuminemia, with low-normal gamma-glutamyl transferase levels. Elastography demonstrated advanced fibrosis (F4), and abdominal computed tomography showed cirrhotic liver changes with splenomegaly. Due to progressive liver failure despite medical therapy, the patient underwent living donor liver transplantation. The explanted liver demonstrated cholestatic hepatitis and cirrhosis, with ductular proliferation and giant-cell transformation, and no evidence of malignancy. Subsequent genetic testing identified a homozygous pathogenic mutation in the HSD3B7 gene, confirming the diagnosis of CBASD1. This case highlights the importance of early biochemical evaluation, urine bile acid profiling, and genetic testing in infants with low gamma-glutamyl transferase (GGT) cholestasis to enable timely diagnosis, continue medical optimization, and proceed with liver transplant in the future.

## Linked entities

- **Genes:** HSD3B7 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7) [NCBI Gene 80270]
- **Diseases:** congenital bile acid synthesis defect type 1 (MONDO:0011906), cirrhosis (MONDO:0005155)

## Full-text entities

- **Genes:** CYP27A1 (cytochrome P450 family 27 subfamily A member 1) [NCBI Gene 1593] {aka CP27, CTX, CYP27}, ACOX2 (acyl-CoA oxidase 2) [NCBI Gene 8309] {aka BCOX, BRCACOX, BRCOX, CBAS6, THCCox}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, HSD3B7 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7) [NCBI Gene 80270] {aka CBAS1, PFIC4, SDR11E3}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, AMACR (alpha-methylacyl-CoA racemase) [NCBI Gene 23600] {aka AMACRD, CBAS4, P504S, RACE, RM}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}
- **Diseases:** bile acid abnormalities (MESH:C567652), coagulopathy (MESH:D001778), failure to thrive (MESH:D005183), Cholestatic Disease (MESH:D002779), vitamin deficiencies (MESH:D014802), hepatobiliary pathologies (MESH:D004066), End-Stage Liver Disease (MESH:D058625), HSD3B7 deficiency (MESH:D007153), viral, autoimmune, or obstructive liver disease (MESH:D014777), hyperbilirubinemia (MESH:D006932), cholestatic jaundice (MESH:D041781), familial intrahepatic cholestasis (MESH:C535932), inborn errors (MESH:D008661), abdominal distension (MESH:D000007), neonatal cholestasis (MESH:D007232), hepatic disease (MESH:D056486), cholestatic liver conditions (MESH:D017093), inborn errors of bile acid metabolism (MESH:D000592), hepatosplenomegaly (MESH:C535727), malignancy (MESH:D009369), conjugated hyperbilirubinemia (MESH:C562885), cirrhotic liver (MESH:D008103), hepatic impairment (MESH:D008107), autosomal recessive conditions (MESH:D020763), cirrhosis (MESH:D005355), cirrhotic (MESH:D000094724), CBASDs (MESH:C535443), autosomal recessive metabolic disorder (MESH:D008659), inherited disorders (MESH:D030342), fat- (MESH:D004620), itching (MESH:D011537), oxysterol 7alpha-hydroxylase deficiency (MESH:C535978), PFIC (MESH:C535933), weight gain (MESH:D015430), skin rashes (MESH:D005076), bleeding (MESH:D006470), splenomegaly (MESH:D013163), CMV (MESH:D003586), fat-soluble vitamin deficiency (MESH:C565532), CMV viremia (MESH:D014766), icterus (MESH:D007565), 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency (MESH:C535442), hypoalbuminemia (MESH:D034141)
- **Chemicals:** CDCA (MESH:D002635), mono-hydroxylated oxo-bile acids (-), bile acid (MESH:D001647), prednisolone (MESH:D011239), Tacrolimus (MESH:D016559), cholestyramine (MESH:D002792), UDCA (MESH:D014580), Steroids (MESH:D013256), 7alpha-hydroxycholesterol (MESH:C011724), sterol (MESH:D013261), C27 (MESH:C006025), CA (MESH:D019826), cholesterol (MESH:D002784), Methylprednisolone (MESH:D008775)
- **Species:** human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.Tyr322Leufs*24, c.963_964insC

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967126/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967126/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967126/full.md

---
Source: https://tomesphere.com/paper/PMC12967126